{"id":44777,"date":"2014-08-21T16:04:01","date_gmt":"2014-08-21T20:04:01","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=voices&#038;p=44777"},"modified":"2014-08-21T16:04:01","modified_gmt":"2014-08-21T20:04:01","slug":"niacin-controversy-what-do-you-say-to-your-patient","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2014\/08\/21\/niacin-controversy-what-do-you-say-to-your-patient\/","title":{"rendered":"The Niacin Controversy: What Do You Say to Your Patient?"},"content":{"rendered":"<p><em>This post is the fifth in our series <a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/voices\/series-what-do-you-say-to-your-patient\/\">\u201cWhat Do You Say to Your Patient?\u201d<\/a> In this series, we ask members to share how they interpret a complex or controversial issue for patients. To review earlier posts, click <a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/voices\/series-what-do-you-say-to-your-patient\/\">here<\/a>.<\/em><\/p>\n<p><i>The following scenario stems from the controversial HPS2-THRIVE study <a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1300955\">published in <\/a><\/i><a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1300955\">The New England Journal of Medicine<\/a><i><a href=\"http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1300955\"> last month<\/a>.<br \/>\n<\/i><\/p>\n<p>Your 62-year-old male patient who has been on statin therapy for 10 years comes in to see you.<\/p>\n<p>For the past five years he has been taking atorvastatin 80 mg and niaspan 2g once daily with no discernible side effects. His LDL is 90 mg\/dl, HDL is 42 mg\/dl, and triglycerides are 120 mg\/dl. He had a PCI 12 years ago, but has had no procedures since.<\/p>\n<p>Your patient recently read in the paper that there is new information about niacin. He asks if there is anything he should know \u2013 and whether his regimen should be changed.<\/p>\n<p><strong><em>What do you tell him?<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In this scenario based on the HPS2-THRIVE study, Harlan Krumholz asks, \u201cWhat do you say to your patient?\u201d<\/p>\n","protected":false},"author":211,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[857],"class_list":["post-44777","post","type-post","status-publish","format-standard","hentry","category-general","tag-niacin"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/44777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/211"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=44777"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/44777\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=44777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=44777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=44777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}